FDA’s Circulatory Systems Devices Panel will turn its attention to evidence needs in the nascent area of leadless cardiac pacemakers at a Feb. 18 meeting, the agency announced in a Dec. 14 Federal Register notice.
The panel is set to discuss and make recommendations on clinical trial, postapproval study design, and physician training requirements for the technology. Panelists will be asked to focus on the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?